Siglec-15 as an emerging target for next-generation cancer immunotherapy

J Sun, Q Lu, MF Sanmamed, J Wang - Clinical Cancer Research, 2021 - AACR
Immunomodulatory agents blocking the PD-1/PD-L1 pathway have shown a new way to
treat cancer. The explanation underlying the success of these agents may be the selective …
被引用次数：101 相关文章

Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy

J Sun, Q Lu, MF Sanmamed… - … cancer research: an …, 2021 - pubmed.ncbi.nlm.nih.gov
Immunomodulatory agents blocking the PD-1/PD-L1 pathway have shown a new way to
treat cancer. The explanation underlying the success of these agents may be the selective …
[HTML] nih.gov

[HTML][HTML] Siglec-15 as an emerging target for next-generation cancer immunotherapy

J Sun, Q Lu, MF Sanmanmed… - Clinical cancer research …, 2021 - ncbi.nlm.nih.gov
Immunomodulatory agents blocking the PD-1/PD-L1 pathway have shown a new way to
treat cancer. The explanation underlying the success of these agents may be the selective …
[PDF] academia.edu

[PDF][PDF] Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy

J Sun, Q Lu, MF Sanmamed, J Wang - Clin Cancer Res, 2021 - academia.edu
Immunomodulatory agents blocking the PD-1/PD-L1 pathway have shown a new way to
treat cancer. The explanation underlying the success of these agents may be the selective …

Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy.

J Sun, Q Lu, MF Sanmamed, J Wang - Clinical Cancer Research: an …, 2020 - europepmc.org
Immunomodulatory agents blocking the PD-1/PD-L1 pathway have shown a new way to
treat cancer. The explanation underlying the success of these agents may be the selective …

Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy.

J Sun, Q Lu, MF Sanmamed, J Wang - Clinical Cancer Research: an …, 2020 - europepmc.org
Immunomodulatory agents blocking the PD-1/PD-L1 pathway have shown a new way to
treat cancer. The explanation underlying the success of these agents may be the selective …